Table 1.
Demographic characteristics of completing participants
| Baseline characteristic | Participants (n = 24) |
|---|---|
| Gender (n[%]) | |
| Male | 14 (58) |
| Female | 10 (42) |
| Age (years) | |
| Median (range) | 68 (58‐82) |
| Symptom duration (years) | |
| Median (range) | 11 (5‐32) |
| Years since diagnosis (years) | |
| Median (range) | 9.5 (4‐30) |
| Symptom fluctuation duration (years) | |
| Median(range) | 4 (1‐20) |
| Most afflicted side (n[%]) | |
| Left | 11 (46) |
| Right | 12 (50) |
| Bilateral | 1 (4) |
| LED (mg/d) | |
| Mean ± SD | 1100 ± 556 |
| LED derived from levodopa (mg/d) | |
| Mean ± SD | 730 ± 330 |
| Dopamine agonists‐LED (mg/d) | |
| Mean ± SD | 129 ± 96a |
| Weight (kg) | |
| Mean ± SD | 74 ± 15 |
| Concomitant PD treatment (n[%]) | |
| Levodopa | 24 (100) |
| Pramipexole | 11 (46) |
| Entacapone | 4 (17) |
| Ropinirole | 5 (21) |
| Rasagiline | 13 (54) |
| Amantadine | 2 (8) |
| Deep brain stimulation | 3 (13) |
LED, levodopa equivalent daily dose; SD, standard deviation; PD, Parkinson's disease
a
Mean data are presented for 16 participants that use dopamine agonists.